On April 28, 2026 EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers with integrated CD2 costimulation, reported the nomination of a development candidate against a solid tumor target as part of its ongoing partnership with AbbVie (NYSE:ABBV). Achievement of this pre-defined preclinical milestone triggers an $18 million milestone payment to EvolveImmune.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The program is being advanced under a collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology initiated between EvolveImmune and AbbVie in October 2024. The collaboration leverages EvolveImmune’s proprietary EVOLVE T cell engager platform, which is designed to deliver potent, selective and integrated T-cell co-stimulation to amplify and sustain the tumor killing capacity of the T-cells. This approach aims to bypass low tumor immunogenicity, conditionally activate adaptive immunity and reduce T-cell dysfunction to overcome therapeutic challenges in solid and hematologic tumors.
"AbbVie has proven to be an exceptional partner, enabling the significant progress we have achieved to date. This is the first program from our collaboration to progress to candidate selection and provides optimism for the continued work we are undertaking with AbbVie against additional targets," said Stephen Bloch, M.D., chief executive officer of EvolveImmune. "Importantly, the achievement of this milestone validates the ability of our EVOLVE platform to deliver potentially differentiated T cell engager candidates in oncology, while also highlighting the exceptional dedication and scientific rigor of our discovery team."
(Press release, EvolveImmune Therapeutics, APR 28, 2026, View Source [SID1234664880])